ライフサイエンスコーパス: Plasmodium yoelii

1 of this family exist in the rodent parasite Plasmodium yoelii.

2 P) identified in the murine malaria parasite Plasmodium yoelii.

3 1 (yMSP1(19)) of the murine malaria parasite Plasmodium yoelii.

4 onocytogenes and the rodent malaria parasite Plasmodium yoelii.

5 ated apicomplexans Plasmodium falciparum and Plasmodium yoelii.

6 -3 fatty acids survive infection with lethal Plasmodium yoelii.

7 vivax, but not the rodent-infective parasite Plasmodium yoelii.

8 ce to pure artemisinin in the rodent malaria Plasmodium yoelii.

9 d gene-targeting techniques to delete PAT in Plasmodium yoelii.

10 rotein (SSP3) in the rodent malaria parasite Plasmodium yoelii.

11 cts on Plasmodium liver stages in vivo using Plasmodium yoelii.

12 imaging (BLI) of the rodent malaria parasite Plasmodium yoelii.

13 tic stages in vivo using the rodent parasite Plasmodium yoelii.

14 ANKA, and by spleen macrophages and DCs from Plasmodium yoelii 17NXL-infected and P. berghei ANKA-inf

15 Here, we test chemically attenuated Plasmodium yoelii 17X and demonstrate significant protec

16 ited in mice infected by the malaria species Plasmodium yoelii 17X NL.

17 ates in response to infection with nonlethal Plasmodium yoelii 17X.

18 coinfected with M. tuberculosis CDC1551 and Plasmodium yoelii 17XL had a lower peak parasitemia and

19 Plasmodium yoelii 17XL infection of mice most closely re

20 ity, studies with animals infected with 10(6)Plasmodium yoelii 17XNL (12 days) were also conducted us

21 We show that co-infection of mice with Plasmodium yoelii 17XNL (Py17XNL) and Salmonella enteric

22 CD47 on the growth and survival of nonlethal Plasmodium yoelii 17XNL (PyNL) malaria in C57BL/6 mice.

23 semisynchronous, Plasmodium berghei ANKA- or Plasmodium yoelii 17XNL-parasitized red blood cells (pRB

24 e to infection with nonlethal murine malaria Plasmodium yoelii 17XNL.

25 on a C57BL/6 background were challenged with Plasmodium yoelii (17XNL strain) sporozoites, and then l

26 e structure and amino acid homology with the Plasmodium yoelii 235-kDa rhoptry protein family, which

27 MCHC of healthy RBCs and RBCs infected with Plasmodium yoelii, a commonly studied rodent parasite mo

28 ls is strongly reduced in mice infected with Plasmodium yoelii, a rodent malaria model.

29 nctions in intact erythrocytes infected with Plasmodium yoelii, a rodent malaria parasite.

30 f biosynthetic machinery to synthesize PABA, Plasmodium yoelii, a rodent malaria species, requires ex

31 Two candidate Plasmodium yoelii adhesion proteins are apical membrane

32 ressing the circumsporozoite (CS) protein of Plasmodium yoelii (AdPyCS), followed by a booster with a

33 the microbial pathogens Candida albicans and Plasmodium yoelii, an accepted experimental malaria mode

34 ane proteins expressed in the gametocytes of Plasmodium yoelii and identify that GEP1 is required for

35 imensional structure of the TRAP A-domain of Plasmodium yoelii and located regions surrounding the MI

36 Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used

37 to be increased in vivo and in vitro during Plasmodium yoelii and P. falciparum intrahepatic develop

38 Studies with Plasmodium yoelii and P. falciparum show that the C-term

39 cytic stages of the rodent malaria parasites Plasmodium yoelii and Plasmodium berghei.

40 liver stages of the rodent malaria parasite Plasmodium yoelii and studied the early events in the de

41 The 235-kDa family of rhoptry proteins in Plasmodium yoelii and the two reticulocyte binding prote

42 ropoiesis are features of malarial anemia in Plasmodium yoelii- and Plasmodium berghei ANKA-infected

43 Rodent models of malaria, commonly Plasmodium yoelii, are frequently used for studies of ma

44 rative in vivo efficacy against erythrocytic Plasmodium yoelii at 25 mg/kg x 4 days via oral route in

45 tope of the circumsporozoite protein (CS) of Plasmodium yoelii between 17D nonstructural proteins NS2

46 surface protein-1 protein vaccines against a Plasmodium yoelii blood-stage challenge.

47 lasmodium falciparum and the rodent parasite Plasmodium yoelii, but its role is not known for Plasmod

48 Targeted deletion of SAP1 in Plasmodium yoelii caused the depletion of a number of se

49 rovided complete protection against a lethal Plasmodium yoelii challenge in mice.

50 ty than AMA1 alone and protects mice against Plasmodium yoelii challenge.

51 We have reported a Plasmodium yoelii chimeric multistage recombinant protei

52 by inserting a B cell epitope derived from a Plasmodium yoelii circumsporozoite (CS) protein (referre

53 tudies using vaccine constructs based on the Plasmodium yoelii circumsporozoite protein (CSP) and P.

54 tion with a naked DNA plasmid expressing the Plasmodium yoelii circumsporozoite protein (pPyCSP) prot

55 Previous studies indicated that the Plasmodium yoelii circumsporozoite protein (PyCSP) 57-70

56 iming with DNA vaccine plasmids encoding the Plasmodium yoelii circumsporozoite protein (PyCSP) and m

57 first immunized as neonates (7 days) with a Plasmodium yoelii circumsporozoite protein (PyCSP) DNA v

58 induce protective CTL responses against the Plasmodium yoelii circumsporozoite protein (PyCSP), BALB

59 lity complex-restricted 9-mer epitope of the Plasmodium yoelii circumsporozoite protein or the nucleo

60 t immunization with plasmid DNA encoding the plasmodium yoelii circumsporozoite protein protected one

61 -) mice infected with a non-lethal strain of Plasmodium yoelii Compared with Cd36(-/-) mice, WT mice

62 Vaccination of mice with yeast-secreted Plasmodium yoelii-derived 19-kilodalton merozoite surfac

63 specific for the circumsporozoite protein of Plasmodium yoelii develop a severely impaired memory res

64 its a dose-dependent blocking effect against Plasmodium yoelii development in An. stephensi.

65 Infection of mice with Plasmodium yoelii elicited infiltration of inflammatory

66 r, here, we show that infection of mice with Plasmodium yoelii enhances S. Typhimurium colonization b

67 We find that during the acute phases of Plasmodium yoelii erythrocyte stage infection, APC upreg

68 that experimental immunization of mice with Plasmodium yoelii fabb/f(-) (Pyfabb/f(-)), a genetically

69 ve immunity induced by immunization with the Plasmodium yoelii fabb/f(-) genetically attenuated paras

70 We disrupted the Plasmodium yoelii gene encoding high mobility group nucl

71 etion of SAP1 in the rodent malaria parasite Plasmodium yoelii generated mutant parasites that traver

72 protracted sterile protection conferred by a Plasmodium yoelii genetically attenuated parasite (PyGAP

73 The sequencing of the Plasmodium yoelii genome, a model rodent malaria parasit

74 Our research shows that apicoplast-targeted Plasmodium yoelii glycerol 3-phosphate dehydrogenase and

75 er stages in the murine malaria model system Plasmodium yoelii has been cumbersome and requires termi

76 ce with sporozoites of Plasmodium berghei or Plasmodium yoelii has been used extensively to evaluate

77 smodium species, like Plasmodium berghei and Plasmodium yoelii, have been used as model species that

78 Plasmodium yoelii hyperparasitemia-resistant mice gavage

79 s a vaccine to induce protective immunity to Plasmodium yoelii in mice and to Plasmodium falciparum i

80 l prophylactic antimalarial activity against Plasmodium yoelii in mouse by oral administration.

81 vivax and Plasmodium berghei, and absent in Plasmodium yoelii In Plasmodium knowlesi, telomeres and

82 alarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice by oral route.

83 ty by oral route against multidrug-resistant Plasmodium yoelii in Swiss mice.

84 accinia virus protein 14K (A27) to the CS of Plasmodium yoelii, induces strong effector memory CD8(+)

85 that specific ablation of Foxp3(+) Tregs in Plasmodium yoelii-infected DEREG-BALB/c mice leads to an

86 e inhibitors for their capacity to eliminate Plasmodium yoelii-infected hepatocytes.

87 n vitro and in vivo and cleared malaria from Plasmodium yoelii-infected mice, resulting in 100% mice

88 tested in vivo in Plasmodium berghei- and/or Plasmodium yoelii-infected mice.

89 D8(+) T-cell-derived IFN-gamma production in Plasmodium yoelii-infected mice.

90 , KAR1123 (109) cured mice with erythrocytic Plasmodium yoelii infection after oral treatment of 25 m

91 d expression of effector cytokines following Plasmodium yoelii infection and are therefore more resis

92 rentiates into mature B cells in response to Plasmodium yoelii infection in mice.

93 at it inhibits PfPSD activity and eliminates Plasmodium yoelii infection in mice.

94 to bites from uninfected mosquitoes prior to Plasmodium yoelii infection influences the local and sys

95 In our experiments, Plasmodium yoelii infection led to a reduced CD8(+) T ce

96 uggest that phenotypic changes in DCs during Plasmodium yoelii infection represent a mechanism of con

97 le of TLR3 in promoting the establishment of Plasmodium yoelii infection through delayed clearance of

98 During a Plasmodium yoelii infection, these regulatory CD11clowCD

99 c mice are altered during the liver stage of Plasmodium yoelii infection.

100 IL-21 expression after resolution of primary Plasmodium yoelii infection.

101 eased T cell responses in the early phase of Plasmodium yoelii infection.

102 rtments throughout the course of blood-stage Plasmodium yoelii infection.

103 bly, several prodiginines cured erythrocytic Plasmodium yoelii infections after oral 25 mg/kg x 4 day

104 genomics protein PY01515 (PDB ID 2aqw) from Plasmodium yoelii, it is shown that the putative annotat

105 teracting partners, as deletion of not1-g in Plasmodium yoelii leads to a comparable or complete arre

106 at identifies host kinases, which facilitate Plasmodium yoelii liver stage infection.

107 ish between lethal and nonlethal blood stage Plasmodium yoelii malaria infections.

108 ra from mice immunized and protected against Plasmodium yoelii malaria, we identified a novel blood-s

109 was shown previously to protect mice against Plasmodium yoelii malaria.

110 Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 pr

111 specific for the C-terminal 19-kDa region of Plasmodium yoelii merozoite surface protein 1 (MSP119),

112 the full-length form and C and N termini of Plasmodium yoelii merozoite surface protein 1 provided p

113 nstrated that, when the C terminus (PyC2) of Plasmodium yoelii merozoite surface protein-1 (MSP-1), a

114 Immunization with Plasmodium yoelii merozoite surface protein-8 (PyMSP-8)

115 n against sporozoite challenge in the rodent Plasmodium yoelii model.

116 regions of MSP1 can also induce protection, Plasmodium yoelii MSP1 was divided into four separate re

117 after oral administration in an erythrocytic Plasmodium yoelii murine malaria model; (3) prevention o

118 Data from a Plasmodium yoelii murine model and cultured human P. fal

119 d curative oral efficacy in the erythrocytic Plasmodium yoelii murine model at both 25 mg/kg x 4 days

120 We used the Plasmodium yoelii murine model to study the potential ro

121 The Plasmodium yoelii murine model was used to test several

122 Previously, using the Plasmodium yoelii murine model, we fused P. yoelii MSP1(

123 Based on proof-of-concept studies in the Plasmodium yoelii murine model, we produced a chimeric v

124 responses to infections with two strains of Plasmodium yoelii (N67 and N67C) and discovered differen

125 alarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in Swiss mice.

126 C57BL/6 mice infected with Plasmodium yoelii nigeriensis N67C display high levels o

127 Typhimurium challenge in mice infected with Plasmodium yoelii nigeriensis.

128 We developed a newborn (NB) mouse Plasmodium yoelii NL infection model to study malaria in

129 ced (Ag-exp) CD4(+) T cell exhaustion during Plasmodium yoelii nonlethal infection occurs alongside t

130 in knockout (beta2M-/-) mice with irradiated Plasmodium yoelii or P. berghei sporozoites.

131 Here, we show that the Plasmodium yoelii orthologs of four Plasmodium falciparu

132 identity with its Plasmodium falciparum and Plasmodium yoelii orthologs, respectively.

133 ws between 19% (Plasmodium berghei) and 26% (Plasmodium yoelii) overall identity to the different Pla

134 gland sporozoites in both rodent-infectious Plasmodium yoelii parasites and human-infectious Plasmod

135 Here, we generated p52/p36-deficient Plasmodium yoelii parasites by the simultaneous deletion

136 Infection of mice with strains of Plasmodium yoelii parasites can result in different path

137 vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodi

138 during infection with virulent and avirulent Plasmodium yoelii parasites in relatively susceptible an

139 etion of the E1 alpha or E3 subunit genes of Plasmodium yoelii PDH caused no defect in blood stage de

140 Epitope-tagged Plasmodium yoelii PlasMei2 was expressed only during liv

141 that BALB/cByJ mice are more susceptible to Plasmodium yoelii preerythrocytic infection than BALB/cJ

142 recently reported the discovery of a 17-kDa Plasmodium yoelii protein expressed in infected hepatocy

143 our reported approach of developing chimeric Plasmodium yoelii proteins to enhance protective efficac

144 Using the murine parasite Plasmodium yoelii (Py) as a model for malaria vaccine de

145 ion of BALB/c mice with a plasmid expressing Plasmodium yoelii (Py) circumsporozoite protein (CSP) in

146 gth surface protein circumsporozoite (CS) of Plasmodium yoelii (Py).

147 Green fluorescent protein-tagged Plasmodium yoelii (PyGFP) was used to efficiently isolat

148 ne encoding the 60-kDa heat shock protein of Plasmodium yoelii (PyHsp60) was cloned into the VR1012 a

149 parasites (Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a revers

150 inia viruses expressing specific antigens of Plasmodium yoelii resulted in a dramatic protective immu

151 ith the genomes of Plasmodium falciparum and Plasmodium yoelii revealed a conserved core of 4500 Plas

152 s study, mice infected with malaria-inducing Plasmodium yoelii revealed that chloroquine treatment co

153 d deletions of the UIS3 and UIS4 loci in the Plasmodium yoelii rodent malaria model (Pyuis3[-] and Py

154 mmunogenicity and efficacy studies using the Plasmodium yoelii rodent model, we tested the ability of

155 that immunization with recombinant CSP from Plasmodium yoelii (rPyCSP), when delivered in Montanide

156 ppression subtractive hybridization (SSH) of Plasmodium yoelii salivary gland sporozoites versus mero

157 reviously, we described the isolation of the Plasmodium yoelii sequence-related molecules P. yoelii M

158 Here we show that dendritic cells presenting Plasmodium yoelii sporozoite antigens are able to activa

159 or immune serum with a luciferase-expressing Plasmodium yoelii sporozoite challenge to assess Ab-medi

160 tibody against the 100-kDa protein inhibited Plasmodium yoelii sporozoite invasion of salivary glands

161 The Plasmodium yoelii sporozoite surface protein 2 (PySSP2)

162 18-amino-acid synthetic linear peptide from Plasmodium yoelii sporozoite surface protein 2 (SSP2) in

163 Here, using mice singly immunized with Plasmodium yoelii sporozoites and high-throughput screen

164 antigen 1 to 2 days prior to challenge with Plasmodium yoelii sporozoites conferred sterile protecti

165 CD8+ T cells induced by Plasmodium yoelii sporozoites develop into protective me

166 of AdPyCS also induced high titers of Abs to Plasmodium yoelii sporozoites in mice.

167 s when coadministered with either irradiated Plasmodium yoelii sporozoites or a recombinant adenoviru

168 in-12 (rmIL-12) 2 days before challenge with Plasmodium yoelii sporozoites protects 100% of mice agai

169 Following immunization with Plasmodium yoelii sporozoites, the CD8(+) T cell populat

170 l (NorSpz) and radiation-attenuated (IrrSpz) Plasmodium yoelii sporozoites.

171 prophylactic activity in mice infected with Plasmodium yoelii sporozoites.

172 experimental human malaria vaccines because Plasmodium yoelii SSP2 is the target of protective CD8+

173 fection, some rodent malaria parasites, like Plasmodium yoelii strain 17XNL (Py17XNL), induce a trans

174 ed survival time of Swiss mice infected with Plasmodium yoelii (strain N-67).

175 unization of mice with Plasmodium berghei or Plasmodium yoelii synthetic linear peptide chimeras (LPC

176 y suboptimal treatment of mice infected with Plasmodium yoelii; these mutants exhibited resistance to

177 study, we characterized the MIF homologue of Plasmodium yoelii throughout the life cycle, with emphas

178 on genomes of three apicomplexan pathogens--Plasmodium yoelii, Toxoplasma gondii, and Cryptosporidiu

179 FN-gamma during experimental infections with Plasmodium yoelii, Toxoplasma gondii, and vaccinia virus

180 ere observed for both Plasmodium berghei and Plasmodium yoelii, two different rodent malaria parasite

181 arly increased in a malaria infection model (Plasmodium yoelii) typified by thrombocytopenia.

182 f two amino acids (I1560N and P2874T) in the Plasmodium yoelii UBP1 can mediate high-level resistance

183 btained when the circumsporozoite protein of Plasmodium yoelii was delivered to DCs.

184 The circumsporozoite protein (PyCSP) of Plasmodium yoelii was engineered into a T. gondii temper

185 Using a model mimicking natural infection by Plasmodium yoelii, we delineated early events governing

186 Using rodent-infectious Plasmodium yoelii, we demonstrate that both gene disrupt

187 TLR9(-/-), and MyD88(-/-) mice infected with Plasmodium yoelii, we show that TLR9 and MyD88 regulate

188 CD47(-/-) mice infected with Plasmodium yoelii, which exhibits an age-based preferenc

189 us gene pairs from Plasmodium falciparum and Plasmodium yoelii, which likely diverged >or=100 million

190 Previously, we identified a Plasmodium yoelii YM 140-kDa merozoite protein, designat

191 a) in the serum and were resistant to lethal plasmodium yoelii YM infection.

192 d PyPNP, the gene encoding PNP in the lethal Plasmodium yoelii YM strain.

193 -1 (MSP-1) from the rodent malarial parasite Plasmodium yoelii yoelii 17XL, expressed as a fusion pro

194 s identified in the rodent malaria parasites Plasmodium yoelii yoelii and Plasmodium berghei.

195 tigene family in the rodent malaria parasite Plasmodium yoelii yoelii code for 235-kilodalton protein

196 reds of DNA vaccines encoding exons from the Plasmodium yoelii yoelii genomic sequence.

197 of protection in vivo to the rodent parasite Plasmodium yoelii yoelii requires Fc receptor bearing ce

198 oxidative phosphorylation of mitochondria of Plasmodium yoelii yoelii trophozoites were assayed in si

199 hole-genome shotgun sequence of one species, Plasmodium yoelii yoelii, and comparative studies with t

200 gous gene families in both P. falciparum and Plasmodium yoelii yoelii, where no orthologs were predic

201 n similar in vivo antimalarial activities in Plasmodium yoelii yoelii-infected mice.

202 C57BL/6J mice were infected with Plasmodium yoelii yoelli 17XNL, and blood and tissues we